Pharvaris Aktie Logo
NL00150005Y4
A2QNWS
PHVS

Pharvaris Aktie

Prévisions

L'objectif de cours moyen des analystes est de 54,08 € (+89,42 %). La médiane est de 55,60 € (+94,75 %).

Acheter
  14
Conserver
  0
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Pharvaris presents Deucrictibant ahead of market launch after strong phase‑III data

    Pharvaris unveiled final plans for Deucrictibant at the Morgan Stanley Healthcare Conference. The oral HAE drug showed Phase‑III efficacy of 87% in HAE types 1 and 2 (83% in the extended population). The company is targeting U.S. approval for on‑demand treatment with a PDUFA target date of April 2027 and is preparing a prophylactic indication thereafter. Management highlighted a favorable safety profile versus competing oral therapies, plans to build a commercial organization (target: ~90 employees) and expects liquidity into mid‑2028 in the base case. Additional data from CREATE and an open‑label extension study are expected to be released in the coming months. » Plus sur de.investing.com


  • Pharvaris shows phase‑III success: Deucrictibant reduces HAE attacks by 87%

    At the Cantor Fitzgerald conference Pharvaris presented phase‑III data (CHAPTER‑3) showing an 87% reduction in hereditary angioedema attacks with the oral B2‑receptor antagonist Deucrictibant. The study included patients from six continents and used an extended‑release formulation that may explain the improved efficacy profile. Safety questions remain: two grade‑3 elevations in liver enzymes and one serious laryngeal event were reported, though the company considers the overall profile comparable to existing prophylactics. Pharvaris plans to launch the on‑demand treatment on April 8, 2025, and aims to file for approval for prophylaxis in the first half of 2025, supported by a targeted commercial platform for bradykinin‑mediated angioedemas. » Plus sur de.investing.com


  • Pharvaris: oral HAE drug deucrictibant shows strong phase‑III data

    Deucrictibant reduced HAE attacks by 87% in the phase‑III prophylaxis study in type‑1/ type‑2 patients (83% in the overall population) and replicated earlier results in a larger, global cohort. Pharvaris expects a PDUFA date for the on‑demand formulation on April 23 and plans to submit the regulatory application for the prophylaxis version in H1 2025. Two cases of elevated liver enzymes were reported but, according to management, are comparable to known risks; long‑term safety is being investigated in the open‑label extension study CHAPTER‑4. Commercially, the company intends to target treatment‑naive patients as well as users of ORLADEYO and injectable therapies. » Plus sur de.investing.com


  • Pharvaris rises sharply after positive phase‑3 data for HAE drug

    Pharvaris reported statistically significant topline results from the pivotal phase‑3 study CHAPTER‑3: Deucrictibant XR reduced the mean monthly HAE attack rate by 83% versus placebo (p<0.0001) and lowered the rate in HAE type 1/2 by 87%. All secondary endpoints were significant and the safety profile proved well tolerated. The company intends to use the data for regulatory submissions, including a New Drug Application in the US in the first half of 2027, and the stock then reached a new 52‑week high. » Plus sur de.investing.com


  • Pharvaris: Phase‑3 study of Deucrictibant XR meets primary endpoint and markedly reduces HAE attacks

    Pharvaris reports that the Phase‑3 CHAPTER‑3 study of Deucrictibant XR met its primary endpoint for prevention of hereditary angioedema (HAE) attacks. A once‑daily 40 mg dose reduced the mean monthly attack rate across all three HAE types by 83% versus placebo and by 87% in HAE types 1 and 2; all secondary endpoints were also statistically significant. Protection began in the first week of treatment and was maintained over 24 weeks. Deucrictibant XR was well tolerated, with no treatment‑related serious adverse events. Pharvaris plans to use the CHAPTER‑3 data to support regulatory filings and intends to submit a New Drug Application to the FDA in the first half of 2027. » Plus sur de.investing.com

En 2022, Pharvaris Aktie a déjà versé 0,10 € de dividendes. Le dernier versement a eu lieu en juillet 2022.

Données financières

Au dernier trimestre, Pharvaris Aktie a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -47,41 M €

(EUR) septembre 2026
YoY
Chiffre d'affaires 0 -
Bénéfice brut 0 -
Bénéfice net -47,41 M 27,67 %
EBITDA -49,99 M 34,33 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
2,02 Md €
Nombre d'actions
70,79 M
Plus haut/bas sur 52 semaines
39,42 € - 21,10 €
Dividendes Non
Bêta
-2,48
Ratio P/E
-10,29
Ratio PEG
-2,45
Ratio P/B
7,57
Ratio P/S
0,00

Profil de l'entreprise

Pharvaris N.V., une société biopharmaceutique en phase de développement clinique, se concentre sur le développement et la commercialisation de thérapies destinées aux maladies rares. La société développe le PHA121, un antagoniste de petite molécule du récepteur B2 de la bradykinine, actuellement en essai clinique de phase II pour le traitement de l'angiœdème héréditaire (AHE). Elle développe également le PHVS416, une capsule molle à libération rapide et à action immédiate destinée aux patients souffrant de crises aiguës d'AHE, actuellement en essai clinique de phase 2 ; ainsi que le PHVS719, un comprimé à libération prolongée à visée prophylactique pour les patients atteints d'AHE, actuellement en essai clinique de phase 1. Elle exerce ses activités aux Pays-Bas, en Suisse et aux États-Unis. La société a été constituée en 2015 et son siège se situe à Leiden, aux Pays-Bas.

Nom
Pharvaris Aktie
PDG
Berndt Modig
Siège social Zug, zh
Pays-Bas
Site web
Secteur
Matériaux
Industrie
Produits chimiques
Introduction en bourse
05/02/2021
Employés 148

Symboles boursiers

Bourse Symbole
NASDAQ
PHVS
Frankfurt
9EN.F
Düsseldorf
9EN.DU
München
9EN.MU
🍪

Parqet  utilise des cookies. En savoir plus